629 related articles for article (PubMed ID: 20415897)
1. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F; Charpentier B; Vanrenterghem Y; Rostaing L; Bresnahan B; Darji P; Massari P; Mondragon-Ramirez GA; Agarwal M; Di Russo G; Lin CS; Garg P; Larsen CP
Am J Transplant; 2010 Mar; 10(3):535-46. PubMed ID: 20415897
[TBL] [Abstract][Full Text] [Related]
2. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
[TBL] [Abstract][Full Text] [Related]
3. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A
Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431
[TBL] [Abstract][Full Text] [Related]
4. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
Rostaing L; Vincenti F; Grinyó J; Rice KM; Bresnahan B; Steinberg S; Gang S; Gaite LE; Moal MC; Mondragón-Ramirez GA; Kothari J; Pupim L; Larsen CP
Am J Transplant; 2013 Nov; 13(11):2875-83. PubMed ID: 24047110
[TBL] [Abstract][Full Text] [Related]
5. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
[TBL] [Abstract][Full Text] [Related]
6. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
[TBL] [Abstract][Full Text] [Related]
8. Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
Charpentier B; Medina Pestana JO; Del C Rial M; Rostaing L; Grinyó J; Vanrenterghem Y; Matas A; Zhang R; Mühlbacher F; Pupim L; Florman S
Am J Transplant; 2013 Nov; 13(11):2884-91. PubMed ID: 24103072
[TBL] [Abstract][Full Text] [Related]
9. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
10. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Vincenti F; Larsen CP; Alberu J; Bresnahan B; Garcia VD; Kothari J; Lang P; Urrea EM; Massari P; Mondragon-Ramirez G; Reyes-Acevedo R; Rice K; Rostaing L; Steinberg S; Xing J; Agarwal M; Harler MB; Charpentier B
Am J Transplant; 2012 Jan; 12(1):210-7. PubMed ID: 21992533
[TBL] [Abstract][Full Text] [Related]
11. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y; Bresnahan B; Campistol J; Durrbach A; Grinyó J; Neumayer HH; Lang P; Larsen CP; Mancilla-Urrea E; Pestana JM; Block A; Duan T; Glicklich A; Gujrathi S; Vincenti F
Transplantation; 2011 May; 91(9):976-83. PubMed ID: 21372756
[TBL] [Abstract][Full Text] [Related]
12. An integrated safety profile analysis of belatacept in kidney transplant recipients.
Grinyó J; Charpentier B; Pestana JM; Vanrenterghem Y; Vincenti F; Reyes-Acevedo R; Apanovitch AM; Gujrathi S; Agarwal M; Thomas D; Larsen CP
Transplantation; 2010 Dec; 90(12):1521-7. PubMed ID: 21088650
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
[TBL] [Abstract][Full Text] [Related]
14. Costimulation blockade with belatacept in renal transplantation.
Vincenti F; Larsen C; Durrbach A; Wekerle T; Nashan B; Blancho G; Lang P; Grinyo J; Halloran PF; Solez K; Hagerty D; Levy E; Zhou W; Natarajan K; Charpentier B;
N Engl J Med; 2005 Aug; 353(8):770-81. PubMed ID: 16120857
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
[TBL] [Abstract][Full Text] [Related]
17. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
Florman S; Vincenti F; Durrbach A; Abouljoud M; Bresnahan B; Garcia VD; Mulloy L; Rice K; Rostaing L; Zayas C; Calderon K; Meier-Kriesche U; Polinsky M; Yang L; Medina Pestana J; Larsen CP
Clin Transplant; 2018 Apr; 32(4):e13225. PubMed ID: 29461660
[TBL] [Abstract][Full Text] [Related]
18. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
19. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
20. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
Martin ST; Powell JT; Patel M; Tsapepas D
Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
